Neratinib Could Be Effective As Monotherapy or in Combination With Trastuzumab in HER2-Low Breast Cancer Cells and Organoid Models

The authors investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids using biochemical methods and cell viability assays.